OTCMWXIBF
Market cap9.18bUSD
Dec 23, Last price
2.17USD
1D
14.21%
1Q
41.83%
IPO
-68.55%
Name
WuXi Biologics (Cayman) Inc
Chart & Performance
Profile
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 17,034,255 11.56% | 15,268,660 48.38% | 10,290,050 83.35% | |||||||
Cost of revenue | 12,788,292 | 10,659,969 | 6,963,315 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 4,245,963 | 4,608,691 | 3,326,735 | |||||||
NOPBT Margin | 24.93% | 30.18% | 32.33% | |||||||
Operating Taxes | 603,179 | 807,865 | 484,538 | |||||||
Tax Rate | 14.21% | 17.53% | 14.56% | |||||||
NOPAT | 3,642,784 | 3,800,826 | 2,842,197 | |||||||
Net income | 3,399,729 -23.09% | 4,420,286 30.45% | 3,388,478 100.63% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (890,758) | (2,768,274) | 8,518,194 | |||||||
BB yield | 0.69% | 1.06% | -2.08% | |||||||
Debt | ||||||||||
Debt current | 731,308 | 1,470,488 | 2,225,456 | |||||||
Long-term debt | 6,244,036 | 4,589,841 | 3,602,710 | |||||||
Deferred revenue | 969,233 | 949,462 | 876,726 | |||||||
Other long-term liabilities | ||||||||||
Net debt | (7,202,379) | (3,044,104) | (5,377,936) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 4,667,712 | 5,541,673 | 3,431,258 | |||||||
CAPEX | (4,045,574) | (5,868,390) | (6,523,114) | |||||||
Cash from investing activities | (3,228,266) | (5,908,252) | (9,601,670) | |||||||
Cash from financing activities | 1,961,163 | (2,591,592) | 8,209,459 | |||||||
FCF | (213,837) | (2,932,842) | (5,226,011) | |||||||
Balance | ||||||||||
Cash | 11,243,437 | 8,714,323 | 11,126,484 | |||||||
Long term investments | 2,934,286 | 390,110 | 79,618 | |||||||
Excess cash | 13,326,010 | 8,341,000 | 10,691,600 | |||||||
Stockholders' equity | 21,938,243 | 14,111,051 | 8,178,784 | |||||||
Invested Capital | 36,222,464 | 32,411,869 | 29,092,634 | |||||||
ROIC | 10.62% | 12.36% | 11.61% | |||||||
ROCE | 8.55% | 11.27% | 8.90% | |||||||
EV | ||||||||||
Common stock shares outstanding | 4,348,874 | 4,375,908 | 4,421,797 | |||||||
Price | 29.60 -50.54% | 59.85 -35.33% | 92.55 -6.84% | |||||||
Market cap | 128,726,685 -50.85% | 261,898,079 -36.00% | 409,237,320 -2.14% | |||||||
EV | 126,702,667 | 260,019,645 | 404,286,957 | |||||||
EBITDA | 5,415,339 | 5,409,365 | 3,808,518 | |||||||
EV/EBITDA | 23.40 | 48.07 | 106.15 | |||||||
Interest | 158,488 | 64,382 | 39,191 | |||||||
Interest/NOPBT | 3.73% | 1.40% | 1.18% |